BridgeBio Pharma (BBIO) Interest Coverage Ratio (2018 - 2026)
BridgeBio Pharma (BBIO) posted Interest Coverage Ratio of 5.22 for Q1 2026, up 64.75% sequentially from 14.8 in Q4 2025, and down 16.28% YoY from 6.23 in Q1 2025.
Powered by 
Analysis
BridgeBio Pharma (BBIO) Interest Coverage Ratio (2018 - 2026) Analysis & Trends
BridgeBio Pharma has reported Interest Coverage Ratio for 9 years, with the latest figure at 5.22 in Q1 2026.
- Quarterly Interest Coverage Ratio fell 16.28% year-over-year to 5.22 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7.94 (down 7.82% YoY) and the FY2025 annual result came in at 0.54, up 33.68% from the prior year.
- Interest Coverage Ratio advanced to 5.22 in Q1 2026 per BBIO's latest filing, from 14.8 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 0.01 in Q1 2024 and troughed at 17.25 in Q4 2024.
- A 5-year average of 6.33 and a median of 5.82 in 2023 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2024 and 2025: Interest Coverage Ratio soared 100.17% in 2024, then plunged 46277.89% in 2025.
- Over 5 years, Interest Coverage Ratio stood at 6.46 in 2022, then climbed by 9.91% to 5.82 in 2023, then plunged by 196.12% to 17.25 in 2024, then advanced by 14.21% to 14.8 in 2025, then jumped by 64.75% to 5.22 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 5.22, 14.8, and 2.34 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | BridgeBio Pharma | 14.65 Bn | 13.93 Bn | 228.63 Mn | -8.06 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -8.06 |
| Mar 31, 2026 | -8.19 |
| Dec 31, 2025 | -11.99 |
| Sep 30, 2025 | -12.37 |
| Jun 30, 2025 | -11.57 |
| Mar 31, 2025 | -5.76 |
| Dec 31, 2024 | -10.50 |
| Sep 30, 2024 | -8.31 |
| Jun 30, 2024 | -7.65 |
| Mar 31, 2024 | 0.01 |
| Dec 31, 2023 | -8.75 |
| Sep 30, 2023 | -7.77 |
| Jun 30, 2023 | -7.09 |
| Mar 31, 2023 | -6.27 |
| Dec 31, 2022 | -6.46 |
| Sep 30, 2022 | -6.51 |
| Jun 30, 2022 | -3.95 |
| Mar 31, 2022 | -8.54 |
| Dec 31, 2021 | -10.94 |
| Sep 30, 2021 | -13.51 |